Britain’s deep-tech sector has produced another attempt to rebuild a piece of physical infrastructure rather than another layer of software, with StandardX raising £10 million to develop an accelerator-based system for manufacturing scarce isotopes used in medicine and, eventually, fusion energy.

StandardX, a London-based company founded in 2025, is developing what it calls an isotope refinery: a compact, high-power particle accelerator intended to manufacture a portfolio of radioactive isotopes rather than being configured around one narrow output. The seed round was led by Vsquared Ventures and East X Ventures, with backing from firstminute capital, the UK Innovation and Science Seed Fund, Brevan Howard Macro Venture, and Geometry.

The company says the financing will support the first production of medical isotopes and development of the underlying accelerator platform. Its public roadmap targets first isotope delivery in 2027, completion of key accelerator subsystems in 2028, and industrial-scale isotope production from 2029, followed by broader deployment and additional materials.

Healthcare provides the first commercial market because radioactive isotopes are used in both diagnostic imaging and targeted cancer treatments. StandardX currently lists astatine-211, copper-64, and zirconium-89 among its initial 2027 materials, with a substantially wider portfolio planned afterwards.

The supply problem is unusual because many isotopes cannot simply be stockpiled. Radioactive decay gives each material a finite useful lifetime, which can force production, processing, transport, and clinical use into tight schedules, while manufacturing is concentrated among specialist reactors and accelerators that are expensive to build and maintain.

A refinery model challenges single-purpose infrastructure

StandardX’s technical argument is that existing production systems impose trade-offs between output, versatility, and deployability. Research reactors can make large quantities of some materials but are costly and geographically concentrated, while conventional cyclotrons and linear accelerators have different constraints around the isotopes they can produce and the economics of doing so.

The company is developing a compact high-power accelerator based on fixed-field alternating-gradient physics. Its intended process sends a high-power particle beam into selected targets to create particular isotopes, after which those materials are extracted and refined for customers.

The refinery description consequently reflects the intended business model rather than simply providing a more dramatic name for an accelerator. StandardX wants one underlying platform to support several materials, allowing production to move between isotopes as demand changes rather than requiring entirely separate infrastructure for each product.

Its technology stack also includes a physics-informed digital twin and machine-learning systems intended to support optimisation and predictive control. In this case, AI is a supporting engineering technology rather than the commercial product itself, because the value of the system will ultimately be determined by physical output, purity, uptime, cost, and the reliability with which isotopes reach customers.

Those requirements make the business substantially harder to scale than software. Particle accelerators involve specialist magnets, power systems, beam control, target materials, radiation protection, cooling, maintenance, and regulatory oversight, while producing the isotope itself is only one stage in a chain that can also involve chemical processing, quality control, transport, and pharmaceutical manufacturing.

Medicine provides the first industrial test

StandardX has chosen medical isotopes as its first market because supply constraints already affect diagnostic and therapeutic programmes. New radiopharmaceuticals are also increasing demand for specialist materials, including isotopes used in theranostics, where radioactive compounds can help identify a tumour and later deliver treatment against the same biological target.

Astatine-211 illustrates the difficulty. The isotope has a half-life of just over seven hours and is being investigated for targeted alpha therapies, but that short lifetime makes production and distribution particularly demanding. StandardX says its accelerator architecture is being developed to increase the output available from both direct and generator-based production routes.

Copper-64 presents a related problem because it is relevant to PET imaging and therapeutic research while also having a relatively short half-life. StandardX intends to include it in its first production portfolio, alongside zirconium-89 and astatine-211, before broadening the range of materials available from the platform.

The company says its first isotopes will be delivered to a clinical partner in 2027, which makes the £10 million round financing for an engineering programme rather than expansion of an established manufacturing operation. Investors are therefore underwriting technical and regulatory execution alongside the existence of market demand.

The accelerator has to reach its intended beam performance, targets must produce commercially useful yields, downstream processes must meet the standards required for the end application, and the complete system must operate reliably enough for customers whose programmes cannot tolerate unpredictable supply.

Fusion provides a longer-range market

StandardX is also designing the platform with fusion-energy materials in mind, particularly tritium. The UK government’s latest fusion investment prospectus identifies the company as part of the British supply-chain ecosystem and describes its accelerator architecture as a potential route towards scalable external tritium production.

That opportunity sits further away than medical isotope supply. Future deuterium-tritium fusion plants will require secure fuel sources and are expected eventually to breed much of their own tritium, but external supply could become valuable during the development and early operation of commercial systems.

Medical demand therefore provides a nearer test of the same underlying technology. If StandardX can demonstrate that one accelerator architecture can manufacture several valuable isotopes reliably, the company will have evidence for a broader industrial platform rather than depending on a fusion market whose scale and timing remain uncertain.

The funding also fits a wider European move towards treating obscure upstream technologies as strategic infrastructure. Isotopes attract less public attention than semiconductors, cloud computing, or batteries, but dependence on a small number of production facilities creates a comparable vulnerability when hospitals, researchers, or industrial operators cannot substitute another material easily.

Building new domestic capacity does not guarantee resilience by itself because production will still depend on target materials, specialist employees, maintenance, transport, regulation, and customers able to handle radioactive products. A versatile accelerator will also have to demonstrate that moving between materials does not undermine utilisation or production economics.

StandardX has nevertheless chosen a problem where scarcity can be measured much more concretely than in many deep-tech investment narratives. The company does not need to invent demand for medical isotopes; it needs to prove that its production architecture can supply an existing market more reliably and flexibly than incumbent infrastructure.

The £10 million round gives it the capital to attempt that proof, but first isotope delivery in 2027 will be only the initial threshold. The harder question is whether the system can repeat the process reliably enough, cheaply enough, and at sufficient volume to become part of Europe’s critical-material supply chain.